Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $14.9 million.

  • Contineum Therapeutics' Cash from Investing Activities rose 149.50% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year increase of 166.94%. This contributed to the annual value of -$69.7 million for FY2024, which is 6.36% down from last year.
  • Per Contineum Therapeutics' latest filing, its Cash from Investing Activities stood at $14.9 million for Q3 2025, which was up 7.61% from $13.9 million recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Cash from Investing Activities peaked at $14.9 million during Q3 2025, and registered a low of -$44.5 million during Q2 2023.
  • In the last 3 years, Contineum Therapeutics' Cash from Investing Activities had a median value of $8.7 million in 2024 and averaged -$8.3 million.
  • As far as peak fluctuations go, Contineum Therapeutics' Cash from Investing Activities slumped by 203.96% in 2024, and later surged by 149.50% in 2025.
  • Quarterly analysis of 3 years shows Contineum Therapeutics' Cash from Investing Activities stood at $9.0 million in 2023, then plummeted by 203.96% to -$9.4 million in 2024, then soared by 149.50% to $14.9 million in 2025.
  • Its Cash from Investing Activities stands at $14.9 million for Q3 2025, versus $13.9 million for Q2 2025 and $14.9 million for Q1 2025.